Imaging epigenetic regulation by histone deacetylases in the brain using PET/MRI with 18F-FAHA

NeuroImage

Volumn 64, Issue 1, 2013, Pages 630-639

  Yeh, Hsin Hsien ^a   Tian, Mei ^a   Hinz, Rainer ^b   Young, Daniel ^a   Shavrin, Alexander ^a   Mukhapadhyay, Uday ^a   Flores, Leo G ^a   Balatoni, Julius ^a   Soghomonyan, Suren ^a   Jeong, Hwan J ^a   Pal, Ashutosh ^a   Uthamanthil, Rajesh ^a   Jackson, James N ^a   Nishii, Ryuichi ^c   Mizuma, Hiroshi ^d   Onoe, Hirotaka ^d   Kagawa, Shinya ^e   Higashi, Tatsuya ^e   Fukumitsu, Nobuyoshi ^f   Alauddin, Mian ^a   Tong, William ^a   Herholz, Karl ^b   Gelovani, Juri G ^a   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c UNIVERSITY OF MIYAZAKI   (Japan)

^d RIKEN   (Japan)

^e Shiga Medical Center Research Institute   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Brain; Epigenetics; Histone deacetylases; Positron emission tomography; Rhesus macaque

Indexed keywords

6 (FLUOROACETAMIDO) 1 HEXANOICANILIDE F 18; FLUOROACETIC ACID; FLUORODEOXYGLUCOSE F 18; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; TRACER; UNCLASSIFIED DRUG; VORINOSTAT;

AMYGDALOID NUCLEUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG HALF LIFE; ENZYME ASSAY; ENZYME REGULATION; ENZYME SPECIFICITY; EPIGENETICS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE ACETYLATION; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; INFERIOR COLLICULUS; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEUS ACCUMBENS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; RADIOACTIVITY; RHESUS MONKEY; TEMPORAL CORTEX;

ANILIDES; ANIMALS; BRAIN; EPIGENESIS, GENETIC; FEMALE; FLUORINE RADIOISOTOPES; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HISTONE DEACETYLASES; MACACA MULATTA; MAGNETIC RESONANCE IMAGING; MALE; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY; SUBTRACTION TECHNIQUE;

EID: 84867593726     PISSN: 10538119     EISSN: 10959572     Source Type: Journal    
DOI: 10.1016/j.neuroimage.2012.09.019     Document Type: Article

References (53)

1. Abel T., Zukin R.S. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr. Opin. Pharmacol. 2008, 8:57-64.
2. Bolger T.A., Yao T.P. Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death. J. Neurosci. 2005, 25:9544-9553.
3. Broide R.S., Redwine J.M., Aftahi N., Young W., Bloom F.E., Winrow C.J. Distribution of histone deacetylases 1-11 in the rat brain. J. Mol. Neurosci. 2007, 31:47-58.
4. Butler R., Bates G.P. Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat. Rev. Neurosci. 2006, 7:784-796.
5. Carrell H.L., Glusker J.P., Villafranca J.J., Mildvan A.S., Dummel R.J., Kun E. Fluorocitrate inhibition of aconitase: relative configuration of inhibitory isomer by x-ray crystallography. Science 1970, 170:1412-1414.
6. Chavez-Blanco A., Segura-Pacheco B., Perez-Cardenas E., Taja-Chayeb L., Cetina L., Candelaria M., Cantu D., Gonzalez-Fierro A., Garcia-Lopez P., Zambrano P., Perez-Plasencia C., Cabrera G., Trejo-Becerril C., Angeles E., Duenas-Gonzalez A. Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study. Mol. Cancer 2005, 4:22.
7. Chawla S., Vanhoutte P., Arnold F.J., Huang C.L., Bading H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J. Neurochem. 2003, 85:151-159.
8. Clarke D.D. Fluoroacetate and fluorocitrate: mechanism of action. Neurochem. Res. 1991, 16:1055-1058.
9. Crepaldi L., Riccio A. Chromatin learns to behave. Epigenetics 2009, 4:23-26.
10. Cui S.S., Yang C.P., Bowen R.C., Bai O., Li X.M., Jiang W., Zhang X. Valproic acid enhances axonal regeneration and recovery of motor function after sciatic nerve axotomy in adult rats. Brain Res. 2003, 975:229-236.
11. Dietz K.C., Casaccia P. HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol. Res. 2010, 62:11-17.
12. Faraco G., Pancani T., Formentini L., Mascagni P., Fossati G., Leoni F., Moroni F., Chiarugi A. Pharmacological inhibition of histone deacetylases by suberoylanilide hydroxamic acid specifically alters gene expression and reduces ischemic injury in the mouse brain. Mol. Pharmacol. 2006, 70:1876-1884.
13. Fischer A., Sananbenesi F., Mungenast A., Tsai L.H. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol. Sci. 2010, 31:605-617.
14. Fonnum F., Johnsen A., Hassel B. Use of fluorocitrate and fluoroacetate in the study of brain metabolism. Glia 1997, 21:106-113.
15. Goncharov N.V., Jenkins R.O., Radilov A.S. Toxicology of fluoroacetate: a review, with possible directions for therapy research. J. Appl. Toxicol. 2006, 26:148-161.
16. Guan Z., Giustetto M., Lomvardas S., Kim J.H., Miniaci M.C., Schwartz J.H., Thanos D., Kandel E.R. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002, 111:483-493.
17. Hendricks J.A., Keliher E.J., Marinelli B., Reiner T., Weissleder R., Mazitschek R. In vivo PET imaging of histone deacetylases by 18F-suberoylanilide hydroxamic acid (18F-SAHA). J. Med. Chem. 2011, 54:5576-5582.
18. Hooker J.M., Kim S.W., Alexoff D., Xu Y., Shea C., Reid A., Volkow N., Fowler J.S. Histone deacetylase inhibitor, MS-275, exhibits poor brain penetration: PK studies of [C]MS-275 using Positron Emission Tomography. ACS Chem. Neurosci. 2010, 1:65-73.
19. Janssen C., Schmalbach S., Boeselt S., Sarlette A., Dengler R., Petri S. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol. 2010, 69:573-581.
20. Jenuwein T., Allis C.D. Translating the histone code. Science 2001, 293:1074-1080.
21. Jiang Y., Langley B., Lubin F.D., Renthal W., Wood M.A., Yasui D.H., Kumar A., Nestler E.J., Akbarian S., Beckel-Mitchener A.C. Epigenetics in the nervous system. J. Neurosci. 2008, 28:11753-11759.
22. Jones P., Altamura S., De Francesco R., Gallinari P., Lahm A., Neddermann P., Rowley M., Serafini S., Steinkuhler C. Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases. Bioorg. Med. Chem. Lett. 2008, 18:1814-1819.
23. Kalda A., Heidmets L.T., Shen H.Y., Zharkovsky A., Chen J.F. Histone deacetylase inhibitors modulates the induction and expression of amphetamine-induced behavioral sensitization partially through an associated learning of the environment in mice. Behav. Brain Res. 2007, 181:76-84.
24. Kazantsev A.G., Thompson L.M. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat. Rev. Drug Discov. 2008, 7:854-868.
25. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., MacGregore-Cortelli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 2005, 23:3923-3931.
26. Kumar A., Choi K.H., Renthal W., Tsankova N.M., Theobald D.E., Truong H.T., Russo S.J., Laplant Q., Sasaki T.S., Whistler K.N., Neve R.L., Self D.W., Nestler E.J. Chromatin remodeling is a key mechanism underlying cocaine-induced plasticity in striatum. Neuron 2005, 48:303-314.
27. Lahm A., Paolini C., Pallaoro M., Nardi M.C., Jones P., Neddermann P., Sambucini S., Bottomley M.J., Lo Surdo P., Carfi A., Koch U., De Francesco R., Steinkuhler C., Gallinari P. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:17335-17340.
28. Lauble H., Kennedy M.C., Emptage M.H., Beinert H., Stout C.D. The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13699-13703.
29. Linseman D.A., Bartley C.M., Le S.S., Laessig T.A., Bouchard R.J., Meintzer M.K., Li M., Heidenreich K.A. Inactivation of the myocyte enhancer factor-2 repressor histone deacetylase-5 by endogenous Ca(2+)//calmodulin-dependent kinase II promotes depolarization-mediated cerebellar granule neuron survival. J. Biol. Chem. 2003, 278:41472-41481.
30. Mai A., Rotili D., Valente S., Kazantsev A.G. Histone deacetylase inhibitors and neurodegenerative disorders: holding the promise. Curr. Pharm. Des. 2009, 15:3940-3957.
31. Majdzadeh N., Morrison B.E., D'Mello S.R. Class IIA HDACs in the regulation of neurodegeneration. Front. Biosci. 2008, 13:1072-1082.
32. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
33. Monti B., Polazzi E., Contestabile A. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr. Mol. Pharmacol. 2009, 2:95-109.
34. 18F-FAHA) for PET Imaging of histone deacetylase (HDAC). J. Labelled Comp. Radiopharm. 2006, 49:997-1006.
35. Nishii R.M.U., Yeh H.-H., Soghomonyan S., Volgin A., Alauddin M.M., Tong W., Gelovani J.G. PET imaging of histone deacetylase activity in a rat brain using 6-([18F]-fluoroacetamide)-1-hexanoicanilide ([18F]-FAHA). J. Nucl. Med. 2007, 48(Supplement 2). (336 pp.).
36. Nishii R., Tong W., Wendt R., Soghomonyan S., Mukhopadhyay U., Balatoni J., Mawlawi O., Bidaut L., Tinkey P., Borne A., Alauddin M., Gonzalez-Lepera C., Yang B., Gelovani J.G. Pharmacokinetics, metabolism, biodistribution, radiation dosimetry, and toxicology of (18)F-fluoroacetate ((18)F-FACE) in non-human primates. Mol. Imaging Biol. 2012, 14(2):213-224.
37. Pandey S.C., Ugale R., Zhang H., Tang L., Prakash A. Brain chromatin remodeling: a novel mechanism of alcoholism. J. Neurosci. 2008, 28:3729-3737.
38. Peters R., Wakelin R.W. Biochemistry of fluoroacetate poisoning; the isolation and some properties of the fluorotricarboxylic acid inhibitor of citrate metabolism. Proc. R. Soc. Lond. B Biol. Sci. 1953, 140:497-507.
39. Pierre K., Pellerin L. Monocarboxylate transporters in the central nervous system: distribution, regulation and function. J. Neurochem. 2005, 94:1-14.
40. Proudfoot A.T., Bradberry S.M., Vale J.A. Sodium fluoroacetate poisoning. Toxicol. Rev. 2006, 25:213-219.
41. Reid A.E., Hooker J., Shumay E., Logan J., Shea C., Kim S.W., Collins S., Xu Y., Volkow N., Fowler J.S. Evaluation of 6-([(18)F]fluoroacetamido)-1-hexanoicanilide for PET imaging of histone deacetylase in the baboon brain. Nucl. Med. Biol. 2009, 36:247-258.
42. Renthal W., Nestler E.J. Histone acetylation in drug addiction. Semin. Cell Dev. Biol. 2009, 20:387-394.
43. Renthal W., Maze I., Krishnan V., Covington H.E., Xiao G., Kumar A., Russo S.J., Graham A., Tsankova N., Kippin T.E., Kerstetter K.A., Neve R.L., Haggarty S.J., McKinsey T.A., Bassel-Duby R., Olson E.N., Nestler E.J. Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli. Neuron 2007, 56:517-529.
44. Ronzoni S., Faretta M., Ballarini M., Pelicci P., Minucci S. New method to detect histone acetylation levels by flow cytometry. Cytometry A 2005, 66:52-61.
45. Ryu H., Smith K., Camelo S.I., Carreras I., Lee J., Iglesias A.H., Dangond F., Cormier K.A., Cudkowicz M.E., Brown R.H., Ferrante R.J. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem. 2005, 93:1087-1098.
46. Sadri-Vakili G., Cha J.H. Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr. Alzheimer Res. 2006, 3:403-408.
47. Sanchis-Segura C., Lopez-Atalaya J.P., Barco A. Selective boosting of transcriptional and behavioral responses to drugs of abuse by histone deacetylase inhibition. Neuropsychopharmacology 2009, 34:2642-2654.
48. Sankaranarayanapillai M., Tong W.P., Maxwell D.S., Pal A., Pang J., Bornmann W.G., Gelovani J.G., Ronen S.M. Detection of histone deacetylase inhibition by noninvasive magnetic resonance spectroscopy. Mol. Cancer Ther. 2006, 5:1325-1334.
49. Thomas E.A. Focal nature of neurological disorders necessitates isotype-selective histone deacetylase (HDAC) inhibitors. Mol. Neurobiol. 2009, 40:33-45.
50. Tian M., Ogawa K., Wendt R., Mukhopadhyay U., Balatoni J., Fukumitsu N., Uthamanthil R., Borne A., Brammer D., Jackson J., Mawlawi O., Yang B., Alauddin M.M., Gelovani J.G. Whole-body biodistribution kinetics, metabolism, and radiation dosimetry estimates of 18F-PEG6-IPQA in nonhuman primates. J. Nucl. Med. 2011, 52:934-941.
51. Tsankova N.M., Berton O., Renthal W., Kumar A., Neve R.L., Nestler E.J. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006, 9:519-525.
52. Tsankova N., Renthal W., Kumar A., Nestler E.J. Epigenetic regulation in psychiatric disorders. Nat. Rev. Neurosci. 2007, 8:355-367.
53. Zeglis B.M., Pillarsetty N., Divilov V., Blasberg R.A., Lewis J.S. The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. Nucl. Med. Biol. 2011, 38:683-696.